Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function

Urology. 2004 Mar;63(3):428-34. doi: 10.1016/j.urology.2003.09.063.

Author

Steven A Kaplan¹

Affiliation

¹ Department of Urology, Columbia-Presbyterian Medical Center, New York, New York 10032, USA.

PMID: 15028431
DOI: 10.1016/j.urology.2003.09.063

No abstract available

Publication types

Research Support, U.S. Gov't, P.H.S.
Review

MeSH terms

5-alpha Reductase Inhibitors
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists / adverse effects
Adrenergic alpha-Antagonists / therapeutic use*
Adult
Aged
Aged, 80 and over
Cardiovascular Diseases / chemically induced
Drug Therapy, Combination
Enzyme Inhibitors / therapeutic use
Humans
Male
Middle Aged
Prostatic Hyperplasia / complications
Prostatic Hyperplasia / drug therapy*
Randomized Controlled Trials as Topic
Receptors, Adrenergic, alpha-1 / classification
Receptors, Adrenergic, alpha-1 / physiology
Rhinitis / chemically induced
Sexual Dysfunction, Physiological / chemically induced
Sexual Dysfunction, Physiological / etiology
Urination Disorders / etiology
Vasodilation / drug effects

Substances

5-alpha Reductase Inhibitors
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Enzyme Inhibitors
Receptors, Adrenergic, alpha-1